



Treatment of Lung Cancer

Guest Editors:

Prof. Dr. Godefridus J. Peters

1. Department of Medical Oncology, Amsterdam University Medical Centers, Amsterdam, The Netherlands

2. Department of Biochemistry, Medical University of Gdansk, Gdansk, Poland

Prof. Dr. Rafal Dziadziuszko

Head, Department of Oncology & Radiotherapy and Early Phase Clinical Trials Centre, Medical University of Gdańsk Ul, Smoluchowskiego 17, 80-214 Gdańsk, Poland

Deadline for manuscript submissions:

closed (10 December 2023)

Message from the Guest Editors

The treatment of lung cancer, especially non-small cell lung cancer (NSCLC), has changed considerably in the last two decades. At the beginning of this century, standard chemotherapy consisted of various doublets, depending on the type of tumor (squamous, non-squamous), while there are also local differences. However, in general, the doublets consisted of gemcitabine/cisplatin, a taxane/cisplatin, and gemcitabine/pemetrexed. For these doublets, a number of potential predictive biomarkers have been investigated, usually focusing on the properties of the single drugs (e.g., drug metabolism, drug transport, DNA repair mechanism). This sometimes led to some extent of personalized therapy. However, with the recognition that many types of adenocarcinoma are addicted to a specific signaling pathway, new types of therapy, often called targeted therapy, have been introduced.

This Special Issue covers all of these aspects in the treatment of lung cancer.





an Open Access Journal by MDPI

Editor-in-Chief

Prof. Dr. Samuel C. Mok

Department of Gynecologic
Oncology and Reproductive
Medicine, The University of Texas
MD Anderson Cancer Center,
Houston, TX 77030, USA

Message from the Editor-in-Chief

Cancers is an international online journal addressing both clinical and basic science issues related to cancer research. The journal is publishing in Open Access format, which will certainly evolve to ensure that the journal takes full advantage of the rapidly changing world of information and knowledge dissemination. It publishes high-quality clinical, translational, and basic science research on cancer prevention, initiation, progression, and treatment, as well as other related topics, particularly to capture the most seminal studies in the rapidly growing area of immunology, immunotherapy, and tumor microenvironment.

Author Benefits

Open Access: free for readers, with article processing charges (APC) paid by authors or their institutions.

High Visibility: indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPlus / SciFinder, and other databases.

Journal Rank: JCR - Q1 (Oncology) / CiteScore - Q1 (Oncology)

Contact Us

Cancers Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland

Tel: +41 61 683 77 34
www.mdpi.com

mdpi.com/journal/cancers
cancers@mdpi.com
[X@Cancers_MDPI](https://twitter.com/Cancers_MDPI)